Want to see AU:PTX full AI Analyst Report?
PTX Stock Chart & Stats
AU$0.07
>-AU$0.01(-8.70%)
At close: 4:00 PM EDT
AU$0.07
>-AU$0.01(-8.70%)
Day’s Range― - ―
52-Week RangeAU$0.04 - AU$0.13
Previous CloseN/A
Volume3.39M
Average Volume (3M)1.07M
Market Cap
AU$71.50M
Enterprise ValueAU$55.34
Total Cash (Recent Filing)AU$9.77M
Total Debt (Recent Filing)AU$495.89K
Price to Earnings (P/E)―
Beta1.31
Next Earnings
Feb 19, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.01
Shares Outstanding1,051,514,500
10 Day Avg. Volume1,190,521
30 Day Avg. Volume1,068,639
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)4.41
Price to Sales (P/S)0.00
P/FCF Ratio-8.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageLimited debt reduces near-term interest and refinancing pressure, preserving financial flexibility while the company advances clinical programs and seeks external funding or partnerships.
Strong Historical Gross MarginThe historical margin profile suggests candidate licensing or collaboration revenue could carry high incremental margins if development programs generate commercial or partnering receipts in the future.
Oncology Platform BreadthA portfolio spanning a CXCR4 antagonist and precision T-cell receptor technology provides multiple development paths and potential partnering opportunities rather than dependence on a single therapeutic concept.
Bears Say
Persistent Operating LossesSustained losses show that current development activities are not self-funding and require continued capital access, increasing execution risk and limiting the company’s ability to absorb setbacks.
Ongoing Cash BurnPersistent cash consumption raises runway risk and makes future equity, debt, licensing, or collaboration funding important to maintain clinical development and corporate operations.
Zero Latest RevenueThe absence of current revenue reduces funding visibility and confirms reliance on future milestones or financing; declining assets and equity indicate that operating burn is consuming the capital base.
Prescient Therapeutics Limited News
PTX FAQ
What was Prescient Therapeutics Limited’s price range in the past 12 months?
Prescient Therapeutics Limited lowest share price was AU$0.04 and its highest was AU$0.13 in the past 12 months.
What is Prescient Therapeutics Limited’s market cap?
Prescient Therapeutics Limited’s market cap is AU$71.50M.
When is Prescient Therapeutics Limited’s upcoming earnings report date?
Prescient Therapeutics Limited’s upcoming earnings report date is Feb 19, 2027 which is in 168 days.
How were Prescient Therapeutics Limited’s earnings last quarter?
Prescient Therapeutics Limited released its earnings results on Aug 20, 2026. The company reported -AU$0.003 earnings per share for the quarter.
Is Prescient Therapeutics Limited overvalued?
According to Wall Street analysts Prescient Therapeutics Limited’s price is currently Overvalued.
Does Prescient Therapeutics Limited pay dividends?
Prescient Therapeutics Limited does not currently pay dividends.
What is Prescient Therapeutics Limited’s EPS estimate?
Prescient Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prescient Therapeutics Limited have?
Prescient Therapeutics Limited has 1,051,514,500 shares outstanding.
What happened to Prescient Therapeutics Limited’s price movement after its last earnings report?
Prescient Therapeutics Limited reported an EPS of -AU$0.003 in its last earnings report. Following the earnings report the stock price went down -2.532%.
Which hedge fund is a major shareholder of Prescient Therapeutics Limited?
Currently, no hedge funds are holding shares in AU:PTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prescient Therapeutics Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:PTX Sentiment 96%
Sector Average ―
Sector Average ―
News Sentiment
Bullish
Bullish news 80%
Bearish news 20%
Bearish news 20%
Technicals
SMA
Positive
20 days / 200 days
Momentum
65.85%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
11.80%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Prescient Therapeutics Limited
Prescient Therapeutics Limited (PTX.AX) is an Australian clinical-stage oncology firm dedicated to creating novel therapeutic agents for various cancer types. The company's primary experimental compound, PTX-200, is currently undergoing several clinical trials: Phase 2a for HER2-negative breast cancer, Phase 1B/2 for acute myeloid leukemia that has relapsed or is resistant to treatment, and Phase 1b for ovarian cancer that is recurrent, persistent, or resistant to platinum-based therapies. Additionally, PTX-100, a RhoA inhibitor, is being developed to target both blood cancers and solid tumors, specifically those characterized by Ras and RhoA genetic mutations. Prescient Therapeutics has also forged a strategic alliance with The University of Texas MD Anderson Cancer Center to advance the development of a blood cancer binder for their OmniCAR platform. Founded in Melbourne, Australia, in 1986, the company operated as Virax Holdings Limited until its rebranding as Prescient Therapeutics Limited in December 2014.
Technical Analysis
Imugene
―
Immutep Ltd
―
Telix Pharmaceuticals
―
Clarity Pharmaceuticals Ltd.
―
Radiopharm Theranostics Limited
―